این سایت در حال حاضر پشتیبانی نمی شود و امکان دارد داده های نشریات بروز نباشند
صفحه اصلی
درباره پایگاه
فهرست سامانه ها
الزامات سامانه ها
فهرست سازمانی
تماس با ما
JCR 2016
جستجوی مقالات
یکشنبه 23 آذر 1404
Iranian Journal of Pathology
، جلد ۱۷، شماره ۲، صفحات ۱۷۴-۱۸۲
عنوان فارسی
چکیده فارسی مقاله
کلیدواژههای فارسی مقاله
عنوان انگلیسی
Diagnostic and Therapeutic Implications of Sortilin Expressed on the Surface of Bladder Carcinoma Cells
چکیده انگلیسی مقاله
Background & Objective:
Cell surface expression of sortilin in different types of cancer signifies it as a therapeutic target for cancer therapy. The aim of this study was to detect sortilin expression in bladder cancer cells using an anti-sortilin monoclonal antibody (mAb) to evaluate sortilin as a target for developing diagnostic and therapeutic agents against bladder carcinoma.
Methods:
The protein expression of sortilin in bladder cancer tissues and cell lines (5637 and EJ138) was investigated by immunohistochemistry (IHC), immune-cytochemistry (ICC), and flow cytometry. Furthermore, the capability of anti-sortilin mAb in apoptosis induction in bladder cancer cells was evaluated.
Results:
A high expression level was observed in bladder carcinoma tissues (
P
≤0.001) and cell lines, using IHC and ICC, respectively. Flow cytometry results showed cell surface expression of 27.5±3% (
P
≤0.01), 74.4±7.8% (
P
≤0.001), and 4.2±0.4% of sortilin in EJ138, 5637, and HFFF cells, respectively. In EJ138 anti-sortilin mAb induced apoptosis in 25.2±11.5% (
P
≤0.05) (early) and 4.5±1.1% (
P
>0.05) (late) after 6 h incubation, while for 12 h, the values of 11.6±3.8% (
P
>0.05) and 20.7±4.4% (
P
≤0.05) were achieved. In 5637 cells, 6 h incubation resulted in 10.2±0.3% (
P
>0.05) and 6.6±1.4% (
P
>0.05) apoptosis induction, while these values were 12.1±0.8% (
P
>0.05) and 27.4±4.5% (
P
≤0.01) after 12 h. The HFFF cells did not show significant apoptosis.
Conclusion:
The overexpression of sortilin in bladder tumor cells and its potential in inducing apoptosis via directed targeting with the specific monoclonal antibody may represent this protein as a potential candidate of targeted therapy in bladder carcinoma.
کلیدواژههای انگلیسی مقاله
Bladder cancer,flow cytometry,monoclonal antibody,Sortilin
نویسندگان مقاله
Ali-Ahmad Bayat |
Monoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran, Iran
Niloufar Sadeghi |
Monoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran, Iran
Ghazaleh Fazli |
Monoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran, Iran
Mohammad Reza Nowroozi |
Uro-Oncology Research Center, Tehran University of Medical Sciences, Tehran, Iran
Solmaz Ohadian Moghadam |
Uro-Oncology Research Center, Tehran University of Medical Sciences, Tehran, Iran
Amin Radmanesh |
Legal Medicine Research Center, Legal Medicine Organization, Tehran, Iran
Mohammadjavad Hedayatshodeh |
Legal Medicine Research Center, Legal Medicine Organization, Tehran, Iran
Ali Reza Sarrafzadeh |
Department of Pathology, Khatam Al Anbia Hospital, Tehran, Iran
Omid Zarei |
Cellular and Molecular Research Center, Research Institute for Health Development, Kurdistan University of Medical Sciences, Sanandaj, Iran
Fatemeh Ghaemimanesh |
Monoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran, Iran
Hodjattallah Rabbani |
Monoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran, Iran
نشانی اینترنتی
https://ijp.iranpath.org/article_251013_593de9c74ebaca607a43ffab815b1e67.pdf
فایل مقاله
فایلی برای مقاله ذخیره نشده است
کد مقاله (doi)
زبان مقاله منتشر شده
en
موضوعات مقاله منتشر شده
نوع مقاله منتشر شده
برگشت به:
صفحه اول پایگاه
|
نسخه مرتبط
|
نشریه مرتبط
|
فهرست نشریات